HDAC3 and cancer: Additionally, compound 8a profiled promising PK properties, and in in vivo assays, it exhibited promising antitumor activity in the 4T1-Lucxenograft model, which is strongly related to HDAC3 impairment, thusconfirming compound 8a as a promising candidate to beevaluated in such cancer types.